Regulatory bodies face several challenges, including keeping up with rapid advancements in cancer research and technology. The complexity of new therapies, such as personalized medicine and immunotherapies, requires updated frameworks for evaluation. Balancing the need for quick access to new treatments with the need for thorough safety evaluations is another challenge. Additionally, global harmonization of regulatory standards remains a significant task.
